Clinical and angiographic outcomes of stent-assisted coiling of paraclinoid aneurysms: Comparison of LVIS and Neuroform stents.

Paraclinoid aneurysms are mainly intradural, and are associated with a potential risk of subarachnoid hemorrhage (SAH). The application of stent-assisted coiling has been widely used in endovascular treatment of intracranial aneurysms. Here we aimed to compare clinical outcomes between low-profile visualized intraluminal support stents (LVIS) and Neuroform (NU) stents. Between January 2013 and December 2017, a total of 101 patients with 118 unruptured paraclinoid aneurysms were embolized by LVIS or NU stents. Procedure-related complications, angiography, and follow-up results were retrospectively analyzed. A total of 45 patients with 54 aneurysms received LVIS stents, and 56 patients with 64 aneurysms received NU stents. Procedure-related complication rate was 6.7% in the LVIS group and 5.4% in the NU group, with no statistical differences between groups (P = 0.511). Compared with the NU group, greater initial complete or near-complete aneurysm obliteration was achieved in the LVIS group (79.6% vs 59.4%, P = 0.0192). DSA angiography follow-up imaging of the 118 aneurysms showed that the LVIS group increased in Raymond-Roy Grade Scale I (RRGS I), however there is no statistical difference (P = 0.32). Compared with NU stents, LVIS stents may achieve greater complete or near-complete occlusion rate immediately post-operation. However, there was no difference in procedural-related complications and follow-up outcomes between LVIS and NU stent groups.

Low-frequency and high-intensity ultrasonic may play a better role in Ultrasound Contrast Agent drug delivery system in vivo.

For the ability to carry drugs and release them at target areas, Ultrasound Contrast Agent (UCA) can be a new vector for drug delivery. Ultrasound makes UCA ruptured so that the drugs it carried can be released. The intensity of medical ultrasound varies wildly. Although low-intensity ultrasound is often used in vitro studies, we think in vivo, the application of high-intensity ultrasound will have better future prospects for drug delivery than low-intensity ultrasonic.